# Ardea Biosciences, Inc. clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Ardea Biosciences, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ardea Biosciences, Inc.: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ardea-biosciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 5, 2017 | NCT03272425 | Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03272425) |
| September 2, 2016 | NCT02888054 | Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02888054) |
| November 20, 2015 | NCT02608710 | RDEA3170 PK/PD Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02608710) |
| October 21, 2015 | NCT02581553 | Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02581553) |
| July 15, 2015 | NCT02498652 | Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects | Ardea Biosciences, Inc. | Phase 2 | Completed | Gout | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02498652) |
| May 19, 2015 | NCT02448368 | RDEA3170 Tablet and Capsule Bioavailability Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02448368) |
| March 25, 2015 | NCT02398448 | IVIVR Assessing PK Parameters Used to Establish Bioequivalence | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02398448) |
| March 19, 2015 | NCT02393560 | DECT Study in Allopurinol-Treated Gout Patients | Ardea Biosciences, Inc. | Observational | Completed | Gout | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02393560) |
| January 13, 2015 | NCT02336594 | RDEA3170 Bioavailability Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02336594) |
| October 31, 2014 | NCT02279641 | RDEA3170 and Allopurinol Combination Study in Gout Subjects | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02279641) |
| September 23, 2014 | NCT02246673 | RDEA3170 and Febuxostat Combination Study in Gout Subjects | Ardea Biosciences, Inc. | Phase 2 | Completed | Gout | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02246673) |
| August 19, 2014 | NCT02219516 | Mild, Moderate and Severe Renal Impairment Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02219516) |
| May 1, 2014 | NCT02127775 | Lesinurad Tablet Bioequivalence | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02127775) |
| January 20, 2014 | NCT02039700 | Bioavailability of Lesinurad and Intravenous \[14C\]Lesinurad | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02039700) |
| January 7, 2014 | NCT02028689 | Metformin and Furosemide Drug-Drug Interaction Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02028689) |
| November 18, 2013 | NCT01986556 | Lesinurad Tablet Relative Bioavailability | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01986556) |
| November 13, 2013 | NCT01982201 | Antacid Interaction Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01982201) |
| August 22, 2013 | NCT01927198 | RDEA3170 Monotherapy in Subjects With Gout | Ardea Biosciences, Inc. | Phase 2 | Completed | Gout | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01927198) |
| July 29, 2013 | NCT01910506 | RDEA3170 AME Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01910506) |
| July 25, 2013 | NCT01908257 | Lesinurad Interaction Study With Ranitidine | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01908257) |
| June 24, 2013 | NCT01884272 | NSAID Drug Interaction Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01884272) |
| June 21, 2013 | NCT01883167 | RDEA3170 and Febuxostat Drug Interaction Study | Ardea Biosciences, Inc. | Phase 1 | Completed | Healthy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01883167) |
| June 7, 2013 | NCT01872832 | Single and Multiple Dose Study in Japanese Subjects | Ardea Biosciences, Inc. | Phase 1 | Completed | Gout | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01872832) |
| March 11, 2013 | NCT01808144 | Lesinurad and Febuxostat Combination Extension Study in Gout | Ardea Biosciences, Inc. | Phase 3 | Completed | Gout | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01808144) |
| March 11, 2013 | NCT01808131 | Lesinurad and Allopurinol Combination Extension Study in Gout | Ardea Biosciences, Inc. | Phase 3 | Completed | Gout | 717 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01808131) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 2 | 7 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Gout | 20 |
| Hyperuricemia | 2 |
| HIV Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [Hospital equipment suppliers in the United States](https://specstream.ai/data/businesses/hospital-equipment-suppliers/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [B2B medical support companies in the United States](https://specstream.ai/data/businesses/b2b-medical-support-companies/united-states)
